<DOC>
	<DOCNO>NCT01600079</DOCNO>
	<brief_summary>This study describe impact vaccination ZOSTAVAX™ epidemiology herpes zoster ( HZ ) cohort vaccinate participant 50 year age old , compare cohort unvaccinated participant .</brief_summary>
	<brief_title>ZOSTAVAX™ ( Zoster Vaccine Live ) Long-term Effectiveness Study ( V211-024 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participants continuous Kaiser Permanente Northern California ( KPNC ) membership since become ageeligible ZOSTAVAX™ 12 month continuous enrollment KPNC study start date</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Varicella-zoster vaccine</keyword>
	<keyword>herpes zoster</keyword>
	<keyword>shingle</keyword>
	<keyword>Varicella-zoster virus</keyword>
	<keyword>postherpetic neuralgia</keyword>
	<keyword>Herpesviridae Infections</keyword>
	<keyword>DNA Virus Infections</keyword>
	<keyword>Virus Diseases</keyword>
</DOC>